38864501|t|Distinct biological property of tau in tau-first cognitive proteinopathy: Evidence by longitudinal clinical neuroimaging profiles and compared with late-onset Alzheimer disease.
38864501|a|BACKGROUND: Tau-first cognitive proteinopathy (TCP) denotes a clinical phenotype of Alzheimer disease (AD) showing Florzolotau(18F) positron emission tomography (PET) positivity but a negative amyloid status. AIM: We explored the biological property of tau using longitudinal cognitive and neuroimaging data in TCP and compared with late-onset AD (LOAD). METHOD: We enrolled 56 patients with LOAD, 34 patients with TCP, and 26 cognitive unimpaired controls. All of the participants had historical data of 2 to 4 three-dimensional T1 images and 2 to 6 annual cognitive evaluations over a follow-up period of 7 years. Tau topography was measured using Florzolotau(18F) PET. In the LOAD and TCP groups, we constructed tau or gray matter clusters covarying with the cognitive measurements. We used mediator analysis to explore the regional tau load as predictor, gray matter partitions as mediators, and significant cognitive test scores as outcomes. Longitudinal cognitive decline and cortical thickness degeneration pattern were analyzed using a linear mixed-effects model. RESULTS: The TCP group had longitudinal declines in nonexecutive domains. The deterministic factor predicting the short-term memory score in TCP was the hippocampal volume and not directly via the medial and lateral temporal tau load. These features formed the conceptual differences with LOAD. DISCUSSION: The biological properties of tau and the longitudinal cognitive-imaging trajectory support the conceptual distinction between TCP and LOAD. TCP represents one specific entity featuring salient short-term memory impairment, declines in nonexecutive domains, a slower gray matter degenerative pattern, and a restricted impact of tau.
38864501	32	35	tau	Gene	4137
38864501	39	42	tau	Gene	4137
38864501	49	72	cognitive proteinopathy	Disease	MESH:D057165
38864501	159	176	Alzheimer disease	Disease	MESH:D000544
38864501	190	193	Tau	Gene	4137
38864501	200	223	cognitive proteinopathy	Disease	MESH:D057165
38864501	225	228	TCP	Disease	MESH:D057165
38864501	262	279	Alzheimer disease	Disease	MESH:D000544
38864501	281	283	AD	Disease	MESH:D000544
38864501	293	304	Florzolotau	Chemical	-
38864501	305	308	18F	Chemical	MESH:C000615276
38864501	371	378	amyloid	Disease	MESH:C000718787
38864501	431	434	tau	Gene	4137
38864501	489	492	TCP	Disease	MESH:D057165
38864501	522	524	AD	Disease	MESH:D000544
38864501	526	530	LOAD	Disease	MESH:D000544
38864501	556	564	patients	Species	9606
38864501	570	574	LOAD	Disease	MESH:D000544
38864501	579	587	patients	Species	9606
38864501	593	596	TCP	Disease	MESH:D057165
38864501	794	797	Tau	Gene	4137
38864501	828	839	Florzolotau	Chemical	-
38864501	840	843	18F	Chemical	MESH:C000615276
38864501	857	861	LOAD	Disease	MESH:D000544
38864501	866	869	TCP	Disease	MESH:D057165
38864501	893	896	tau	Gene	4137
38864501	1014	1017	tau	Gene	4137
38864501	1138	1155	cognitive decline	Disease	MESH:D003072
38864501	1263	1266	TCP	Disease	MESH:D057165
38864501	1391	1394	TCP	Disease	MESH:D057165
38864501	1475	1478	tau	Gene	4137
38864501	1539	1543	LOAD	Disease	MESH:D000544
38864501	1586	1589	tau	Gene	4137
38864501	1683	1686	TCP	Disease	MESH:D057165
38864501	1691	1695	LOAD	Disease	MESH:D000544
38864501	1697	1700	TCP	Disease	MESH:D057165
38864501	1761	1778	memory impairment	Disease	MESH:D008569
38864501	1884	1887	tau	Gene	4137
38864501	Association	MESH:C000615276	4137
38864501	Association	MESH:D008569	4137
38864501	Association	MESH:D057165	4137
38864501	Association	MESH:D000544	4137

